In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...
Read More
In a nutshell This study looked at the safety and effectiveness of tirzepatide (LY-3298176) in patients with type 2 diabetes (T2D) inadequately controlled by diet and exercise alone. It found that compared to placebo, tirzepatide improved diabetes control and weight in these patients. Some background In T2D, there is a resistance of the...
Read More
In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...
Read More
In a nutshell This study evaluated the effectiveness and safety of idelalisib (Zydelig) combined with rituximab (Rituxan) in the treatment of patients with chronic lymphocytic leukemia (CLL) in a real-world setting. The data supported the effectiveness of this regimen in routine practice for these patients. Some background Idelalisib (IDL) is an...
Read More
In a nutshell This study assessed the effectiveness of bazedoxifene (Duavee) in the prevention of bone loss in patients with rheumatoid arthritis (RA) while receiving low-dose glucocorticoid (GC) treatments. The data showed improved bone mineral density (BMD) and reduced bone turnover markers (BTMs) in these patients. Some background RA is a...
Read More
In a nutshell This study evaluated the safety of eliminating routine postoperative blood tests after conducting robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer (PCa) and proposed recommendations for their use. Some background Localized prostate cancer (PCa) refers to cancer that is confined to the prostate...
Read More
In a nutshell This study investigated the clinical benefits and safety of FMS-like tyrosine kinase 3 inhibitors (FLT3i) in various treatment stages of acute myeloid leukemia (AML). The data showed that FLT3is safely improved prognosis in the induction stage (first-line treatment) of newly diagnosed FLT3-positive AML and salvage therapy (treatment...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of nivolumab (Opdivo) in combination with carboplatin (C; Paraplatin) and paclitaxel (P; Taxol) plus bevacizumab (B; Avastin) as first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSCLC). The data showed that nivolumab plus BCP...
Read More
In a nutshell This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term. Some background Melanoma is an aggressive...
Read More
In a nutshell This study evaluated the effectiveness and safety of regorafenib (Stivarga) versus TAS-102 (Lonsurf; trifluridine-tipiracil) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that both treatments were safe and lead to similar survival outcomes for primary and secondary treatment of...
Read More
In a nutshell This study looked at vagus nerve stimulation (VNS) as a treatment for arm weakness after stroke. It found that VNS combined with standard rehabilitation improved arm function significantly more than standard rehab alone. Some background After a stroke, some nerves do not work as they should. This means that the muscles...
Read More
In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...
Read More
